EA201991027A9 - ANTIBODIES AGAINST CD38 AND FUSED PROTEINS WITH A LOWERENED ALPHA-2b INTERFERON - Google Patents

ANTIBODIES AGAINST CD38 AND FUSED PROTEINS WITH A LOWERENED ALPHA-2b INTERFERON

Info

Publication number
EA201991027A9
EA201991027A9 EA201991027A EA201991027A EA201991027A9 EA 201991027 A9 EA201991027 A9 EA 201991027A9 EA 201991027 A EA201991027 A EA 201991027A EA 201991027 A EA201991027 A EA 201991027A EA 201991027 A9 EA201991027 A9 EA 201991027A9
Authority
EA
Eurasian Patent Office
Prior art keywords
alpha
lowerened
interferon
antibodies against
fused proteins
Prior art date
Application number
EA201991027A
Other languages
Russian (ru)
Other versions
EA201991027A1 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to EA201991027A priority Critical patent/EA201991027A9/en
Publication of EA201991027A1 publication Critical patent/EA201991027A1/en
Publication of EA201991027A9 publication Critical patent/EA201991027A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Представлены антитела, специфически связывающиеся с CD38, так же как конструкции, содержащие такие антитела, слитые с белками ослабленного интерферона альфа-2b. Слитые конструкции анти-CD38-ослабленный интерферон альфа-2b можно использовать для ингибирования пролиферации злокачественных клеток, которые экспрессируют как CD38, так и рецептор для IFN-альфа-2b, так же как для индукции апоптоза в таких клетках. Ингибирование пролиферации и индукция апоптоза злокачественных клеток может служить в качестве фундамента для лечения лежащей в основе злокачественной опухоли.Antibodies specifically binding to CD38 are provided, as are constructs containing such antibodies fused to proteins of attenuated interferon alpha-2b. The anti-CD38-attenuated interferon alpha-2b fusion constructs can be used to inhibit the proliferation of cancer cells that express both CD38 and the receptor for IFN-alpha-2b, as well as to induce apoptosis in such cells. Inhibition of proliferation and apoptosis of malignant cells can serve as a foundation for the treatment of the underlying malignant tumor.

EA201991027A 2013-04-29 2013-04-29 ANTIBODIES AGAINST CD38 AND FUSED PROTEINS WITH A LOWERENED ALPHA-2b INTERFERON EA201991027A9 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EA201991027A EA201991027A9 (en) 2013-04-29 2013-04-29 ANTIBODIES AGAINST CD38 AND FUSED PROTEINS WITH A LOWERENED ALPHA-2b INTERFERON

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EA201991027A EA201991027A9 (en) 2013-04-29 2013-04-29 ANTIBODIES AGAINST CD38 AND FUSED PROTEINS WITH A LOWERENED ALPHA-2b INTERFERON

Publications (2)

Publication Number Publication Date
EA201991027A1 EA201991027A1 (en) 2019-09-30
EA201991027A9 true EA201991027A9 (en) 2019-11-27

Family

ID=68048696

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991027A EA201991027A9 (en) 2013-04-29 2013-04-29 ANTIBODIES AGAINST CD38 AND FUSED PROTEINS WITH A LOWERENED ALPHA-2b INTERFERON

Country Status (1)

Country Link
EA (1) EA201991027A9 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220251234A1 (en) * 2019-07-16 2022-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity for cd38 and uses thereof

Also Published As

Publication number Publication date
EA201991027A1 (en) 2019-09-30

Similar Documents

Publication Publication Date Title
EA201592076A1 (en) ANTIBODIES AGAINST CD38 AND FUSE PROTEINS WITH A LITTLE ALPHA-2B INTERFERON
EA201691824A1 (en) ANTIBODIES AGAINST EGFRVIII AND THEIR APPLICATIONS
CO2018001624A2 (en) Anti-dll3-antibody antibody conjugates and methods of use
EA201891366A1 (en) HUMANIZED ANTIBODIES AGAINST CD73
PH12016502267A1 (en) Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
EA201591611A1 (en) CONJUGATES ANTIBODY AND MEDICINE
MX2021002728A (en) Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors.
EA201400991A1 (en) COMBINED THERAPY USING ANTIBODIES TO HUMAN CSF-1R AND ITS APPLICATIONS
EP3964527A3 (en) Combination therapy for cancer
EA201591801A1 (en) DRUG ANTIBODIES
MX2019004193A (en) Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer.
PH12015502112A1 (en) Cancer treatment using antibodies that bind cell surface grp78
EA201600354A1 (en) ANTIGENSOUND MOLECULE CONTAINING A VARIABLE AREA OF ANTIBODY
EA201690080A1 (en) APPLICATION OF SEMAFORIN-4D INHIBITING MOLECULES IN COMBINATION WITH IMMUNOMODULATING THERAPY TO INHIBIT GROWTH AND METASTASIS OF TUMORS
EA201790334A1 (en) Conjugates Anti-CDH6 Antibodies With Medicinal Products
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
MX2018006249A (en) Novel anti-emr2 antibodies and methods of use.
EA201690992A1 (en) ANTIBODIES SPECIFIC TO FCRN
NZ607472A (en) Treatment for neoplastic diseases
EA201992513A1 (en) BREAST CANCER TREATMENT METHOD
EA201390955A1 (en) ROBO1-FC fusion protein for use in the treatment of hepatocarcinoma
MX2018007817A (en) Novel anti-mmp16 antibodies and methods of use.
EA201991027A9 (en) ANTIBODIES AGAINST CD38 AND FUSED PROTEINS WITH A LOWERENED ALPHA-2b INTERFERON
EA201691889A1 (en) ANTIBODIES AGAINST ANG2
MX2018007818A (en) Novel anti-upk1b antibodies and methods of use.